Annual general meeting

Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders

Retrieved on: 
Wednesday, January 11, 2023
Professional corporation, Mass meeting, Security (finance), Name, European Medicines Agency, Interview, Sarissa, England and Wales, Ropes & Gray, Special, Chair, Chairperson, FDC, Our Boarding House, Burn, Growth, Corporate governance, Investment, Annual general meeting, Management, Audit, Renewable energy, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital Management LP (“Sarissa”) to convene a General Meeting of Shareholders (the “Special Meeting”).

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital Management LP (“Sarissa”) to convene a General Meeting of Shareholders (the “Special Meeting”).
  • As appropriate, Amarin will announce the date of the Special Meeting and the record date for shareholders to vote at the Special Meeting in due course, and Amarin shareholders are not required to take any action at this time.
  • Since Sarissa’s position was made public in November 2021, Amarin has engaged actively with Sarissa.
  • We believe Sarissa’s proxy contest is misguided, costly and not in the best interest of other Amarin shareholders at this critical time for the Company.

Tyson Foods to Hold Annual Meeting of Shareholders

Retrieved on: 
Tuesday, January 10, 2023
Tyson Foods, TSN, Annual general meeting, NYSE, Meat

SPRINGDALE, Ark., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) will hold its Annual Meeting of Shareholders on Thursday, February 9, 2023 at 11 a.m. Eastern time (10 a.m. Central time) at Tyson Foods, 319 E. Emma Ave., Springdale, Arkansas 72762.

Key Points: 
  • SPRINGDALE, Ark., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN) will hold its Annual Meeting of Shareholders on Thursday, February 9, 2023 at 11 a.m. Eastern time (10 a.m. Central time) at Tyson Foods, 319 E. Emma Ave., Springdale, Arkansas 72762.
  • A ticket, proof of shareholder status or team member badge is required for entry.
  • Participants may join the audio-only version of the conference call by calling:
    Please note: All dial-in participants should ask to join the Tyson Foods call.
  • For those who cannot participate at the scheduled time, a replay of the live webcast will be available at http://ir.tyson.com .

Lincoln Electric Schedules 2023 Virtual Annual Meeting of Shareholders

Retrieved on: 
Tuesday, January 10, 2023
Eastern Time Zone, LECO, Annual general meeting, Shareholder, Food delivery, Lobster

CLEVELAND, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Lincoln Electric Holdings, Inc. (the “Company”) (Nasdaq: LECO) today announced that the Company’s 2023 Annual Meeting of Shareholders will be held as a virtual meeting on Wednesday, April 19, 2023 at 11:00 a.m., Eastern Time.

Key Points: 

CLEVELAND, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Lincoln Electric Holdings, Inc. (the “Company”) (Nasdaq: LECO) today announced that the Company’s 2023 Annual Meeting of Shareholders will be held as a virtual meeting on Wednesday, April 19, 2023 at 11:00 a.m., Eastern Time.

Integer to Exhibit at NANS 2023 Annual Meeting

Retrieved on: 
Tuesday, January 10, 2023
Lithium, Medtech, NANS, North American Neuromodulation Society, NYSE, Miniaturization, Integer, MDO, Original equipment manufacturer, FC, Acquisition, Commercialization, Annual general meeting, Medical device

PLANO, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will exhibit at the 26th North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace Convention Center in Las Vegas, Nevada, from Jan. 12 – 14, 2023, joining medtech leaders and innovators from around the world.

Key Points: 
  • PLANO, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will exhibit at the 26th North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace Convention Center in Las Vegas, Nevada, from Jan. 12 – 14, 2023, joining medtech leaders and innovators from around the world.
  • Attendees are invited to visit Integer at booth #525 to learn more about Integer’s breadth and depth of innovative medical device manufacturing, design and development capabilities.
  • This encompasses expanded implantable neuromodulation lead offerings as a result of the acquisition of Oscor in December 2021.
  • During NANS, Integer will unveil its latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable devices.

The First of Long Island Corporation Announces Additional Board Refreshment as Part of Ongoing Commitment to Strong Corporate Governance

Retrieved on: 
Monday, January 9, 2023
Security (finance), Annual general meeting, Meeting, First National Bank, Knowledge, Management

MELVILLE, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- The First of Long Island Corporation (the “Company”) (Nasdaq: FLIC), the parent company of The First National Bank of Long Island (the “Bank”), announced that as part of its ongoing board refreshment program, it has agreed to nominate J. Abbott R. Cooper for election to the Board of Directors (the “Board”) of the Company at the 2023 Annual Meeting of Shareholders (the “Annual Meeting”).

Key Points: 
  • MELVILLE, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- The First of Long Island Corporation (the “Company”) (Nasdaq: FLIC), the parent company of The First National Bank of Long Island (the “Bank”), announced that as part of its ongoing board refreshment program, it has agreed to nominate J. Abbott R. Cooper for election to the Board of Directors (the “Board”) of the Company at the 2023 Annual Meeting of Shareholders (the “Annual Meeting”).
  • Assuming Mr. Cooper is elected at the 2023 Annual Meeting, the Company will have added two new, independent directors since November 2022.
  • “I am excited to join The First of Long Island Corporation’s Board at this next stage in the Bank’s transformation toward a more commercially focused business model.
  • I have been impressed with the progress made to date under the leadership of CEO Chris Becker and how the Board has sharpened its focus on increasing shareholder value.

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
IND, Luman Hamlin Weller, Non-Hodgkin lymphoma, Science, MHRA, Lymphoma, Therapy, Gilead Sciences, IKZF1, BTK, Biotechnology, Standby Equity Distribution Agreement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Safety, CLL, FDA, IKZF3, Immunotherapy, Head, ASH, Conference, Innovation, Lymphatic system, Food, Health care, Chronic lymphocytic leukemia, Society for Immunotherapy of Cancer, Patient, Cancer, SAN, Clinical trial, Sale, SITC, Annual general meeting, Pharmaceutical industry, Vaccine, Sanofi

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated milestones for 2023 and provided an overview of recent progress in a presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in H2 2023 based on emerging clinical data and feedback from the U.S. Food and Drug Administration (FDA).
  • In addition, Nurix expects to define a dose for Phase 1b cohort expansion in H2 2023.
  • New drug candidate: Nurix expects to select a new targeted protein degrader development candidate in 2023.
  • Research milestones: Nurix expects to achieve substantial research collaboration milestones throughout 2023 from its existing collaborations with Gilead Sciences and Sanofi.

Pharvaris Provides Regulatory, Clinical, and Corporate Updates

Retrieved on: 
Monday, January 9, 2023
Attack, AAAAI, Trial of the century, Safety, FDA, HAE, Food and Drug Administration, American Academy of Allergy, Asthma, and Immunology, Hereditary angioedema, American Academy, Toxicology, Annual general meeting, Oral, Pharmaceutical industry

ZUG, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights.

Key Points: 
  • ZUG, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today provided business updates and company highlights.
  • Pharvaris will conduct a 26-week rodent toxicology study to resolve the clinical holds in the U.S.
  • Based on the Company’s current assumptions regarding ex-U.S. regulatory status and enrollment, Pharvaris anticipates announcing top-line data from the CHAPTER-1 trial in 2H2023.
  • Pharvaris remains diligent in its operational management and is focusing on its existing clinical HAE pipeline to extend runway into 4Q2024.

Polished.com Has Scheduled its Annual Meeting of Stockholders for January 19, 2023

Retrieved on: 
Monday, January 9, 2023
Online Retail, Home Goods, Retail, Annual general meeting, NYSE American, Polished, NYSE

Polished.com Inc. (NYSE: POL) (formerly known as 1847 Goedeker Inc.) (“Polished” or the “Company”), a content-driven and technology-enabled shopping destination for appliances, furniture and home goods in the U.S. household appliances market, today reiterated that it has scheduled its annual meeting of stockholders (the “Annual Meeting”) for January 19, 2023, as indicated in the Company’s Definitive Proxy Statement filed with the U.S. Securities Exchange Commission on December 19, 2022.

Key Points: 
  • Polished.com Inc. (NYSE: POL) (formerly known as 1847 Goedeker Inc.) (“Polished” or the “Company”), a content-driven and technology-enabled shopping destination for appliances, furniture and home goods in the U.S. household appliances market, today reiterated that it has scheduled its annual meeting of stockholders (the “Annual Meeting”) for January 19, 2023, as indicated in the Company’s Definitive Proxy Statement filed with the U.S. Securities Exchange Commission on December 19, 2022.
  • On January 3, 2023, NYSE American sent Polished a letter stating that the Company was not in compliance with Section 704 of the NYSE American Company Guide because it had not yet held its Annual Meeting.
  • Polished expects to cure this instance of non-compliance, which is not anticipated to impact the trading of its common stock or warrants, upon holding its Annual Meeting this month.

Eros Media World Plc Announces It Will Not Appeal NYSE Delisting

Retrieved on: 
Monday, January 9, 2023
Professional Services, Entertainment, Technology, Film & Motion Pictures, Other Technology, Finance, Annual report, NYSE, Annual general meeting, Isle, Media

Eros Media World PLC (“Eros Media”, “Eros” or the “Company”) (NYSE: EMWP), a global Indian media and entertainment company announces that it will not submit any further appeal with the New York Stock Exchange (“NYSE”) to review the determination made by the NYSE to commence proceedings to delist the Company’s A ordinary shares and suspend trading immediately (the “Staff Determination”).

Key Points: 
  • Eros Media World PLC (“Eros Media”, “Eros” or the “Company”) (NYSE: EMWP), a global Indian media and entertainment company announces that it will not submit any further appeal with the New York Stock Exchange (“NYSE”) to review the determination made by the NYSE to commence proceedings to delist the Company’s A ordinary shares and suspend trading immediately (the “Staff Determination”).
  • The Staff Determination was based on the Company’s inability to file its annual reports on Form 20-F for the years ending March 31, 2021 and March 31, 2022.
  • In order to file a compliant annual report, the Company would have to include audited financials statements of STX Filmworks, Inc., the Company’s accounting predecessor, for the fiscal years ended March 31, 2019 and March 31, 2020.
  • The Company sought relief from the SEC to omit these historical financial statements from the delayed Form 20-F for the years ending March 31, 2021 and March 31, 2022, but was not able to obtain such relief.

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Research, Technology, Neurology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, IND, Type 2, Hart–Scott–Rodino Antitrust Improvements Act, Publication, Therapy, CNS, TYK2, LRRK2, Strategic planning, FDA, Pancreatic serous cystadenoma, Psoriasis, Neurology, Astex, MALT1, Ulcerative colitis, ASH, Manuscript, CDC7, Drug discovery, Takeda, Patient, Drug design, Webcast, Software, Ajax, MBBS, Blog, Society, UC, Bristol Myers Squibb, Annual general meeting, Ōtsuka, Pharmaceutical industry, Nimbus

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its strategic priorities for 2023.
  • Schrödinger reported a new program targeting LRRK2, a genetically validated target with therapeutic potential for the treatment of Parkinson’s disease.
  • In 2022, Schrödinger generated cryo-electron microscopy structures of LRRK2 which is helping to accelerate the identification of novel LRRK2 inhibitors.
  • Today Schrödinger outlined the following strategic priorities for 2023:
    Schrödinger will report its fourth quarter and full-year financial results and provide 2023 financial guidance on Tuesday, February 28, 2023, after the financial markets close.